- Samsung Biologics reported second-quarter 2026 revenue of KRW 1,321 billion and operating profit of KRW 586 billion, with cumulative CDMO contract value reaching USD 21.6 billion.
- The company continued expanding its global manufacturing network, opened a Netherlands sales office, invested in life sciences innovation, and reaffirmed its 2026 guidance.
Samsung Biologics reported financial results for the second quarter of fiscal year 2026, posting revenue of KRW 1,321 billion and operating profit of KRW 586 billion. For the first half of 2026, the CDMO recorded revenue of KRW 2,578 billion and operating profit of KRW 1,167 billion. Cumulative contract value reached USD 21.6 billion, reflecting demand for the company’s integrated development, contract manufacturing, and CDMO services.
The company said second-quarter performance was supported by stable manufacturing operations across Plants 1 through 4 and execution of ongoing client programs. Compared with the same period last year, second-quarter revenue increased from KRW 1,014.2 billion, while operating profit rose from KRW 477.2 billion.
During the quarter, Samsung Biologics continued integrating its Rockville manufacturing facility in Maryland into its global manufacturing network while maintaining commercial operations at the site. Plant 5 remained on schedule for its planned ramp-up, with Process Performance Qualification activities progressing. The company also opened a sales office in the Netherlands during the third quarter of 2026 to strengthen regional support for clients across Europe.
Samsung Biologics also expanded its Life Science Fund activities through investments in Cartography Biosciences and the creation of a third Life Science Fund with an additional KRW 200 billion investment. The company said it plans to further develop its proprietary platform technologies to strengthen CDMO capabilities across multiple modalities. It was also included in the Dow Jones Best-in-Class Indices for the fifth consecutive year and published its annual ESG report.
“We delivered another quarter of solid execution while making meaningful progress on our growth strategy. Our continued investments in global operations and future capabilities are strengthening the foundation of our business and preparing us for the next phase of industry growth.”
John Rim, President and CEO of Samsung Biologics
